Medicine and Dentistry
Abdominal Compartment Syndrome
20%
Abdominal Pressure
5%
ALK Inhibitor
20%
Anaplastic Lymphoma Kinase
20%
Biopsy
20%
Cancer
10%
Cancer Diagnostics
10%
Chronic Myelomonocytic Leukemia
20%
Clinical Decision Making
20%
Clinical Trial
6%
Decision Making
15%
Diagnosis
30%
Epidermal Growth Factor Receptor
42%
Exon
9%
Gene Fusion
6%
Immunohistochemistry
20%
In Vitro
6%
Intraabdominal Hypertension
20%
Language Processing
5%
Malignant Neoplasm
52%
Molecular Diagnosis
25%
Molecular Diagnostics
8%
Molecular Pathology
8%
Molecular Profiling
10%
Neoplasm
88%
Next Generation Sequencing
12%
Non Small Cell Lung Cancer
100%
Oncologist
10%
Overall Survival
5%
Pancreatitis
5%
Pathologist
8%
Personalized Medicine
5%
Prevalence
14%
Progression Free Survival
9%
Resistance Mutation
20%
Somatics
20%
Targeted Therapy
51%
Tumor Cell
5%
Keyphrases
Abdominal Compartment Syndrome
20%
Actionable Variants
5%
Automatic Data Processing
20%
Cancer Cases
15%
Cancer Diagnostics
10%
Chronic Myeloid Leukemia
20%
Clinical Trials
7%
Confidence Interval
13%
Diagnostic Challenge
20%
EGFR Inhibitors
5%
EGFR mutation
22%
EGFR Testing
5%
Exon 19 Deletion
7%
Genetic Modification
15%
Groningen
28%
Initial Diagnosis
10%
Intra-abdominal Hypertension
20%
Intra-abdominal Pressure
5%
Isocitrate Dehydrogenase 1 (IDH1)
10%
Kinase Inhibitor Therapy
5%
L858R
8%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Malignancy
10%
Median Progression-free Survival
5%
Metagenomic Next-generation Sequencing (mNGS)
10%
Mixed Cancer
20%
Molecular Diagnostics
20%
Molecular Profile
5%
Molecular Profiling
10%
Molecular Tumor Board
40%
Mutational Profile
40%
Netherlands
5%
Non-small Cell Lung Cancer (NSCLC)
40%
Non-small Cell Lung Cancer Patients
8%
Non-target-site Resistance
8%
Oncogenic mutations
10%
Pan-TRK Immunohistochemistry
20%
Pancreatitis
5%
Pattern-based
20%
PIK3CA
10%
Profiling Techniques
10%
Rare Variants
10%
Routine Testing
20%
Stimulator of Interferon Genes Pathways
6%
STING1
20%
Survival Trends
20%
Targeted Therapy
28%
Treatment Outcome
5%
Tumor-infiltrating
10%
University Medical Centre
28%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Compartment Syndrome
20%
Anaplastic Lymphoma Kinase
20%
Anaplastic Lymphoma Kinase Inhibitor
20%
Dabrafenib
20%
Epidermal Growth Factor Receptor
28%
Intraabdominal Hypertension
20%
Malignant Neoplasm
12%
Neoplasm
62%
Non Small Cell Lung Cancer
80%
Osimertinib
20%
Overall Survival
5%
Pancreatitis
5%
Prevalence
14%
Progression Free Survival
8%
Trametinib
20%
